Cited by 1,862Influenza Virus Research StudiesCarbohydrate Chemistry and SynthesisComputational Drug Discovery Methods

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Rational design of potent sialidase-based inhibitors of influenza virus replication

von Itzstein, Mark, Wu, Wen-Yang, Kok, Gaik B., Pegg, Michael S., Dyason, Jeffrey C., Jin, Betty, Van Phan, Tho, Smythe, Mark L., White, Hume F., Oliver, Stuart W., Colman, Peter M., Varghese, Joseph N., Ryan, D. Michael, Woods, Jacqueline M., Bethell, Richard C., Hotham, Vanessa J., Cameron, Janet M., Penn, Charles R.·1993·Nature

DOI 10.1038/363418a0

Open this paper in CoChat — free account

Abstract

Two potent inhibitors based on the crystal structure of influenza virus sialidase have been designed. These compounds are effective inhibitors not only of the enzyme, but also of the virus in cell culture and in animal models. The results provide an example of the power of rational, computer-assisted drug design, as well as indicating significant progress in the development of a new therapeutic or prophylactic treatment for influenza infection.

Integrity signals

Registry

Crossref · 10.1038/363418a0

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

A computational procedure for determining energetically favorable binding sites on biologically important macromolecules
Goodford, P. J. (1985) · Journal of Medicinal Chemistry · doi:10.1021/jm00145a002 · Cited by 2,642
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution
Wilson, I. A., Skehel, J. J., & Wiley, D. C. (1981) · Nature · doi:10.1038/289366a0 · Cited by 2,537
Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation
Wiley, D. C., Wilson, I. A., & Skehel, J. J. (1981) · Nature · doi:10.1038/289373a0 · Cited by 1,623
Influenza virus M2 protein has ion channel activity
Pinto, L. H., Holsinger, L. J., & Lamb, R. A. (1992) · Cell · doi:10.1016/0092-8674(92)90452-i · Cited by 1,230
Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution
Varghese, J. N., Laver, W. G., & Colman, P. M. (1983) · Nature · doi:10.1038/303035a0 · Cited by 891
Self-citation
The molecular basis of the specific anti‐influenza action of amantadine.
Hay, A. J., Wolstenholme, A. J., Skehel, J. J., & Smith, M. H. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb04038.x · Cited by 855
Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-d-N-acetylneuraminate) substrate
Potier, M., Mameli, L., Bélisle, M., Dallaire, L., & Melançon, S. B. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90362-2 · Cited by 816
Structure of the catalytic and antigenic sites in influenza virus neuraminidase
Colman, P. M., Varghese, J. N., & Laver, W. G. (1983) · Nature · doi:10.1038/303041a0 · Cited by 806
Self-citation
Characterization of temperature sensitive influenza virus mutants defective in neuraminidase
Palese, P., Tobita, K., Ueda, M., & Compans, R. W. (1974) · Virology · doi:10.1016/0042-6822(74)90276-1 · Cited by 788
A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors
Henderson, P. J. F. (1972) · Biochemical Journal · doi:10.1042/bj1270321 · Cited by 524

Flagged first, then by citations

Show all 38 references

Research works printed but not linked: 6

Chong, A. K. J., Pegg, M. S. & von Itzstein, M. Biochem. Int. 24, 165–171 (1991).
Gottschalk, A. Biochim. biophys. Acta 23, 645–646 (1957). · DOI
Colman, P. M. & Ward, C. W. Curr. Top. microbiol. Immun. 114, 117–255 (1985).
Palese, P. & Schulman, J. L. in Chemoprophylaxis and Virus Infections of the Upper Respiratory Tract Vol. 1 (ed. Oxford, J. S.) 189–205 (CRC, Cleveland, 1977).
von Itzstein, M., Jin, B., Wu, W.-Y. & Chandler, M. Carbohydr. Res. (in the press).
von Itzstein, M., Wu, W.-Y., Phan, T. V., Danylec, B. & Jin, B. Chem. Abs. 117, 49151y (1991).

Sorted by citations

Biological roles of glycans
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“The elegant structure-based design of a modified version of the previously known sialidase inhibitor Neu5Ac2en (791) gave rise to the potent and specific inhibitor zanamivir (Relenza) (792, 793), and later to the structurally related agent oseltamivir (Tamiflu) (794, 795).”
Background
Chemical Glycobiology
Bertozzi, C. R., & Kiessling, A. L. L. (2001) · Science · doi:10.1126/science.1059820 · Cited by 1,942
Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Self-citation
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation
Jones, G., Willett, P., & Glen, R. C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(95)80037-9 · Cited by 1,548
Approved Antiviral Drugs over the Past 50 Years
Clercq, E. D., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,477
Virtual screening of chemical libraries
Shoichet, B. K. (2004) · Nature · doi:10.1038/nature03197 · Cited by 1,425
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C., Lim, S., Xia, W., Lee, H., Chan, L.-C., Kuo, C., Khoo, K., Chang, S.-S., Cha, J., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,136
Influenza Neuraminidase Inhibitors Possessing a Novel Hydrophobic Interaction in the Enzyme Active Site: Design, Synthesis, and Structural Analysis of Carbocyclic Sialic Acid Analogues with Potent Anti-Influenza Activity
Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M. S., Mendel, D. B., Tai, C. Y., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja963036t · Cited by 1,100
Neuraminidase Inhibitors for Influenza
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050740 · Cited by 1,103
Mechanisms of enzymatic glycoside hydrolysis
McCarter, J. D., & Withers, G. (1994) · Current Opinion in Structural Biology · doi:10.1016/0959-440x(94)90271-2 · Cited by 910
3D-QSAR in Drug Design - A Review
Verma, J. K., Khedkar, V. M., & Coutinho, E. C. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790232260 · Cited by 837
From carbohydrate leads to glycomimetic drugs
Ernst, B., & Magnani, J. L. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2852 · Cited by 835
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
Russell, R. J. M., Haire, L. F., Stevens, D. J., Collins, P. J., Lin, Y. P., Blackburn, G. M., Hay, A. J., Gamblin, S. J., & Skehel, J. J. (2006) · Nature · doi:10.1038/nature05114 · Cited by 822
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
Nicholson, K., Aoki, F., Osterhaus, A., Trottier, S., Carewicz, O., Mercier, C., Rode, A., Kinnersley, N., & Ward, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02288-1 · Cited by 785
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Kiso, M., Mitamura, K., Sakai‐Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N., & Kawaoka, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16934-1 · Cited by 785
Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing
Patil, R., Das, S., Stanley, A., Yadav, L., Sudhakar, A., & Varma, A. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012029 · Cited by 802
Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections
Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762
Influenza virus neuraminidase inhibitors
Gubareva, L. V., Kaiser, L., & Hayden, F. G. (2000) · The Lancet · doi:10.1016/s0140-6736(99)11433-8 · Cited by 739
Glycosidase inhibitors: update and perspectives on practical use
Asano, N. (2003) · Glycobiology · doi:10.1093/glycob/cwg090 · Cited by 717
The war against influenza: discovery and development of sialidase inhibitors
von Itzstein, M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2400 · Cited by 705
Influenza: lessons from past pandemics, warnings from current incidents
Horimoto, T., & Kawaoka, Y. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1208 · Cited by 695
Antiviral agents active against influenza A viruses
Clercq, E. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2175 · Cited by 677
Strategies in the design of antiviral drugs
Clercq, E. D. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd703 · Cited by 667
Living Coordination Polymerization of Allene Derivatives Bearing Hydroxy Groups by π-Allylnickel Catalyst
Taguchi, M., Tomita, I., & Endō, T. (2000) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20001016)39:20 · Cited by 59
Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review
Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113705 · Cited by 665
Use of molecular docking computational tools in drug discovery
Stanzione, F., Giangreco, I., & Cole, J. C. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.004 · Cited by 689
In silico methods and tools for drug discovery
Shaker, B., Ahmad, S., Lee, J., Jung, C., & Na, D. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104851 · Cited by 669
Functional balance between haemagglutinin and neuraminidase in influenza virus infections
Wagner, R., Matrosovich, M. N., & Klenk, H. (2002) · Reviews in Medical Virology · doi:10.1002/rmv.352 · Cited by 608
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials
Dobson, J., Whitley, R. J., Pocock, S., & Monto, A. S. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62449-1 · Cited by 598
Binding of Small-Molecule Ligands to Proteins: “What You See” Is Not Always “What You Get”
Mobley, D. L., & Dill, K. A. (2009) · Structure · doi:10.1016/j.str.2009.02.010 · Cited by 598
Diversity of Microbial Sialic Acid Metabolism
Vimr, E. R., Kalivoda, K. A., Deszo, E. L., & Steenbergen, S. M. (2004) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.68.1.132-153.2004 · Cited by 585
Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza: Randomized Controlled Trials for Prevention and Treatment
Hayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M., Kinnersley, N., Mills, R. G., Ward, P., & Straus, S. E. (1999) · JAMA · doi:10.1001/jama.282.13.1240 · Cited by 550
Pandemic Threat Posed by Avian Influenza A Viruses
Horimoto, T., & Kawaoka, Y. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.1.129-149.2001 · Cited by 550
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants
Collins, P. J., Haire, L. F., Lin, Y. P., Liu, J., Russell, R. J. M., Walker, P. A., Skehel, J. J., Martin, S. R., Hay, A. J., & Gamblin, S. J. (2008) · Nature · doi:10.1038/nature06956 · Cited by 539
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.977-981.2002 · Cited by 508
Ensemble Docking in Drug Discovery
Amaro, R. E., Baudry, J. Y., Chodera, J. D., Demir, Ö., McCammon, J. A., Miao, Y., & Smith, J. C. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.02.038 · Cited by 503
Exploitation of glycosylation in enveloped virus pathobiology
Watanabe, Y., Bowden, T. A., Wilson, I. A., & Crispin, M. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.05.012 · Cited by 489
Structure of the Hemagglutinin Precursor Cleavage Site, a Determinant of Influenza Pathogenicity and the Origin of the Labile Conformation
Chen, J., Lee, K. H., Steinhauer, D. A., Stevens, D. J., Skehel, J. J., & Wiley, D. C. (1998) · Cell · doi:10.1016/s0092-8674(00)81771-7 · Cited by 476
Sialic Acids in Molecular and Cellular Interactions
Kelm, S., & Schauer, R. (1997) · International review of cytology · doi:10.1016/s0074-7696(08)62127-0 · Cited by 458
On the Nature of the Multivalency Effect: A Thermodynamic Model
Kitov, P. I., & Bundle, D. R. (2003) · Journal of the American Chemical Society · doi:10.1021/ja038223n · Cited by 445
Drug resistance in influenza A virus: the epidemiology and management
Hussain, M., Galvin, H. D., Haw, T. Y., Nutsford, A. N., & Husain, M. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s105473 · Cited by 451
Evidence for Zanamivir Resistance in an Immunocompromised Child Infected with Influenza B Virus
Gubareva, L. V., Matrosovich, M. N., Brenner, M. K., Bethell, R. C., & Webster, R. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/314440 · Cited by 430
Self-citation
Sialobiology of Influenza: Molecular Mechanism of Host Range Variation of Influenza Viruses
Suzuki, Y. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.399 · Cited by 424
Emerging principles for the therapeutic exploitation of glycosylation
Dalziel, M., Crispin, M., Scanlan, C. N., Zitzmann, N., & Dwek, R. A. (2014) · Science · doi:10.1126/science.1235681 · Cited by 447
Structure, function and metabolism of sialic acids
Traving, C., & Schauer, R. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050258 · Cited by 424
Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Talele, T. T., Khedkar, S. A., & Rigby, A. C. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790232251 · Cited by 420
Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802
He, G. Z., Massarella, J. W., & Ward, P. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937060-00003 · Cited by 415
Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract
Flerlage, T., Boyd, D. F., Meliopoulos, V., Thomas, P. G., & Schultz‐Cherry, S. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00542-7 · Cited by 419
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Han, B., He, X., Liu, Y., He, G., Peng, C. Y., & Li, J. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00196a · Cited by 409
An Overview of Drug Discovery and Development
Berdigaliyev, N., & Aljofan, M. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0307 · Cited by 431
Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase.
Taylor, G. L., Crennell, S. J., Takimoto, T., & Portner, A. (2000) · Nature Structural Biology · doi:10.1038/81002 · Cited by 392
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
McKimm‐Breschkin, J. L. (2012) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12047 · Cited by 392
Balanced Hemagglutinin and Neuraminidase Activities Are Critical for Efficient Replication of Influenza A Virus
Mitnaul, L. J., Matrosovich, M. N., Castrucci, M. R., Tuzikov, A. B., Bovin, N. V., Kobasa, D., & Kawaoka, Y. (2000) · Journal of Virology · doi:10.1128/jvi.74.13.6015-6020.2000 · Cited by 389
Application and Limitations of X‐ray Crystallographic Data in Structure‐Based Ligand and Drug Design
Davis, A. M., Teague, S. J., & Kleywegt, G. J. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200539 · Cited by 386
The sweet spot: defining virus–sialic acid interactions
Stencel-Baerenwald, J., Reiß, K., Reiter, D. M., Stehle, T., & Dermody, T. S. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3346 · Cited by 388
BCX-1812 (RWJ-270201): Discovery of a Novel, Highly Potent, Orally Active, and Selective Influenza Neuraminidase Inhibitor through Structure-Based Drug Design
Babu, Y. S., Chand, P., Bantia, S., Kotian, P. L., Dehghani, A., El-Kattan, Y. A., Lin, T., Hutchison, T. L., Elliott, A. J., Parker, C. D., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002679 · Cited by 385
Antivirals and antiviral strategies
Clercq, E. D. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro975 · Cited by 378
Animal Models for Influenza Virus Pathogenesis and Transmission
Bouvier, N. M., & Lowen, A. C. (2010) · Viruses · doi:10.3390/v20801530 · Cited by 378
Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use
Monto, A. S., McKimm‐Breschkin, J. L., Macken, C. A., Hampson, A. W., Hay, A. J., Klimov, A. I., Tashiro, M., Webster, R. G., Aymard, M., Hayden, F. G., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01339-05 · Cited by 364
Pressure induced amorphization of materials
Sharma, S. M., & Sikka, S. K. (1996) · Progress in Materials Science · doi:10.1016/0079-6425(95)00006-2 · Cited by 349
Recent advances in computer-aided drug design
Song, C. M., Lim, S. J., & Tong, J. (2009) · Briefings in Bioinformatics · doi:10.1093/bib/bbp023 · Cited by 349
Dihydropyrancarboxamides Related to Zanamivir: A New Series of Inhibitors of Influenza Virus Sialidases. 1. Discovery, Synthesis, Biological Activity, and Structure−Activity Relationships of 4-Guanidino- and 4-Amino-4H-pyran-6-carboxamides
Smith, P. W., Sollis, S. L., Howes, P. D., Cherry, P. C., Starkey, I. D., Cobley, K. N., Weston, H. E., Scicinski, J. J., Merritt, A., Whittington, A. R., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970374b · Cited by 342
Self-citation
Keynote review: Structural biology and drug discovery
Congreve, M., Murray, C. W., & Blundell, T. L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03484-7 · Cited by 342
Influenza virus neuraminidase: Structure, antibodies, and inhibitors
Colman, P. M. (1994) · Protein Science · doi:10.1002/pro.5560031007 · Cited by 334
Self-citation
Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy
Clercq, E. D., & Field, H. J. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706446 · Cited by 332
Structure-based drug design: progress, results and challenges
Verlinde, C. L. M. J., & Hol, W. G. J. (1994) · Structure · doi:10.1016/s0969-2126(00)00060-5 · Cited by 331
Structures of influenza A proteins and insights into antiviral drug targets
Das, K., Aramini, J. M., Ma, L.-C., Krug, R. M., & Arnold, E. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1779 · Cited by 330
Synthesis of chiral pharmaceutical intermediates by biocatalysis
Patel, R. N. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2007.10.031 · Cited by 329
What Can We Learn from Molecular Recognition in Protein–Ligand Complexes for the Design of New Drugs?
Böhm, H., & Klebe, G. (1996) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199625881 · Cited by 328
Exploration of the Sialic Acid World
Schauer, R., & Kamerling, J. P. (2018) · Advances in carbohydrate chemistry and biochemistry · doi:10.1016/bs.accb.2018.09.001 · Cited by 328
Resistance of influenza viruses to neuraminidase inhibitors — a review
McKimm‐Breschkin, J. L. (2000) · Antiviral Research · doi:10.1016/s0166-3542(00)00103-0 · Cited by 321
Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
(1998) · The Lancet · doi:10.1016/s0140-6736(98)10190-3 · Cited by 351
Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion
Russell, R. J. M., Kerry, P. S., Stevens, D. J., Steinhauer, D. A., Martin, S. R., Gamblin, S. J., & Skehel, J. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807142105 · Cited by 314
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro
Woods, J. M., Bethell, R. C., Coates, J. A., Healy, N., Hiscox, S. A., Pearson, B. A., Ryan, D., Ticehurst, J. R., Tilling, J., & Walcott, S. M. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.7.1473 · Cited by 312
Self-citation
Microbial recognition of target-cell glycoconjugates
Karlsson, K. (1995) · Current Opinion in Structural Biology · doi:10.1016/0959-440x(95)80054-9 · Cited by 310
Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol
Ленева, И. А., Russell, R. J. M., Boriskin, Y. S., & Hay, A. J. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2008.10.009 · Cited by 309
Assignment of the Absolute Configuration of Polyfunctional Compounds by NMR Using Chiral Derivatizing Agents
Seco, J. M., Quiñoá, E., & Riguera, R. (2012) · Chemical Reviews · doi:10.1021/cr2003344 · Cited by 294
Structure−Activity Relationship Studies of Novel Carbocyclic Influenza Neuraminidase Inhibitors
Kim, C. U., Lew, W., Williams, M. A., Wu, H., Zhang, L., Chen, X., Escarpe, P. A., Mendel, D. B., Laver, W. G., & Stevens, R. C. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980162u · Cited by 293
Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir
McKimm‐Breschkin, J. L., Trivedi, T., Hampson, A. W., Hay, A. J., Klimov, A. I., Tashiro, M., Hayden, F. G., & Zambon, M. C. F. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2264-2272.2003 · Cited by 291
Safety and Efficacy of the Neuraminidase Inhibitor GG167 in Experimental Human Influenza
Hayden, F. G. (1996) · JAMA · doi:10.1001/jama.1996.03530280047035 · Cited by 291
Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms
Kirchmair, J., Williamson, M. J., Tyzack, J. D., Tan, L., Bond, P. J., Bender, A., & Glen, R. C. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200542m · Cited by 297
Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution
Zeng, Q., Langereis, M. A., van Vliet, A. L. W., Huizinga, E. G., & de Groot, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800502105 · Cited by 293
Synthesis and Biological Activity of Natural Aminocyclopentitol Glycosidase Inhibitors: Mannostatins, Trehazolin, Allosamidins, and Their Analogues
Berecibar, A., Grandjean, C., & Siriwardena, A. H. (1999) · Chemical Reviews · doi:10.1021/cr980033l · Cited by 293
Biochemical engineering of the N-acyl side chain of sialic acid: biological implications
Keppler, O. T., Horstkorte, R., Pawlita, M., Schmidt, C., & Reutter, W. G. (2001) · Glycobiology · doi:10.1093/glycob/11.2.11r · Cited by 288
Classification of Water Molecules in Protein Binding Sites
Barillari, C., Taylor, J., Viner, R., & Essex, J. W. (2007) · Journal of the American Chemical Society · doi:10.1021/ja066980q · Cited by 285
Novel Chemical Space Exploration via Natural Products
Rosén, J., Gottfries, J., Mureşan, S., Backlund, A., & Oprea, T. I. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801514w · Cited by 284
Antiviral Drugs
Balfour, H. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904223401608 · Cited by 286
Docking Screens for Novel Ligands Conferring New Biology
Irwin, J. J., & Shoichet, B. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b02008 · Cited by 284
Next generation 3D pharmacophore modeling
Schaller, D., Šribar, D., Noonan, T., Deng, L., Nguyen, T. N., Pach, S., Machalz, D., Bermúdez, M., & Wolber, G. (2020) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1468 · Cited by 297
Efficacy and Safety of the Neuraminidase Inhibitor Zanamivirin the Treatment of Influenza A and B Virus Infections
Monto, A. S., Fleming, D., Henry, D. C., de Groot, R., Mäkelä, M. J., Klein, T., Elliott, M., Keene, O. N., & Man, C. Y. (1999) · The Journal of Infectious Diseases · doi:10.1086/314904 · Cited by 273
Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery
Muhammed, M. T., & Aki, E. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220922103109 · Cited by 292
Herpesviruses as unrecognised components of the pathogenesis of chronic diseases
Griffiths, P. D. (2000) · Reviews in Medical Virology · doi:10.1002/1099-1654(200009/10)10:5 · Cited by 3
Structural Characterization of the 1918 Influenza Virus H1N1 Neuraminidase
Xu, X., Zhu, X., Dwek, R. A., Stevens, J., & Wilson, I. A. (2008) · Journal of Virology · doi:10.1128/jvi.00959-08 · Cited by 265
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 266
Oral Administration of a Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 Protects Mice and Ferrets against Influenza Infection
Mendel, D. B., Tai, C. Y., Escarpe, P. A., Li, W., Sidwell, R. W., Huffman, J. H., Sweet, C., Jakeman, K. J., Merson, J. R., Lacy, S. A., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.640 · Cited by 253
Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase
Colman, P. M., Hoyne, P. A., & Lawrence, M. C. (1993) · Journal of Virology · doi:10.1128/jvi.67.6.2972-2980.1993 · Cited by 255
Self-citation
The structural basis for an essential subunit interaction in influenza virus RNA polymerase
OBAYASHI, E., Yoshida, H., Kawai, F., Shibayama, N., Kawaguchi, A., Nagata, K., Tame, J. R. H., & Park, S. (2008) · Nature · doi:10.1038/nature07225 · Cited by 267
Influenza neuraminidase
Air, G. M. (2011) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2011.00304.x · Cited by 247
Glycosidase inhibition: assessing mimicry of the transition state
Gloster, T. M., & Davies, G. J. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b915870g · Cited by 253

Authors: von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., Colman, P. M., Varghese, J. N., Ryan, D. M., Woods, J. M., Bethell, R. C., Hotham, V. J., Cameron, J. M., & Penn, C. R.
Affiliations: Monash University (AU)
Commonwealth Scientific and Industrial Research Organisation (AU)
ORCID: Smythe, Mark L.
Colman, Peter M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1993-06
Volume: 363
Issue: 6428
Pages: 418-423
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/363418a0
OpenAlex: W2086358466
Cited by: 1,862
References: 38
Citations by year: 2026: 27 · 2025: 25 · 2024: 34 · 2023: 30 · 2022: 46 · 2021: 50 · 2020: 60 · 2019: 50 · 2018: 58 · 2017: 45 · 2016: 68 · 2015: 48 · 2014: 71 · 2013: 83 · 2012: 84
FWCI: 58.57
Type: journal article
Language: en
Update notices: correction (1993-10-28)
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Griffith Research Online (submittedVersion)
Topics: Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords: influenza virus, sialidase inhibitors, neuraminidase, rational drug design, computer-aided drug design, antiviral agents, influenza treatment, prophylaxis, enzyme inhibition
MeSH terms: Animals, Antiviral Agents, Cell Line, Disease Models, Animal, Female, Ferrets, Guanidines, Humans, Influenza, Human, Models, Molecular, Neuraminidase, Influenza A virus, Viral Plaque Assay, Pyrans, Sheep, Sialic Acids, Virus Replication, Drug Design, Computer-Aided Design, Mice, Zanamivir

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rational design of potent sialidase-based inhibitors of influenza virus replication

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks